Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Introducing NARCAN® Nasal Spray to Dental Emergency Medical Kits

As the opioid crisis continues to spread, HealthFirst recognizes the need for dental offices to be equipped to respond to opioid overdoses. Following the recommendation of its Medical Advisory Board, HealthFirst has added NARCAN Nasal Spray to all SM Series Basic Emergency Medical Kits. This easy-to-administer drug could save a life in your practice. Harsh Reality…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from HealthFirst on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

As the opioid crisis continues to spread, HealthFirst recognizes the need for dental offices to be equipped to respond to opioid overdoses. Following the recommendation of its Medical Advisory Board, HealthFirst has added NARCAN Nasal Spray to all SM Series Basic Emergency Medical Kits. This easy-to-administer drug could save a life in your practice.

Harsh Reality of the Opioid Epidemic

The United States Centers for Disease Control and Prevention estimates that opioid overdoses claim an average of 115 American lives each day. This class of drug, which includes painkillers, heroin, and fentanyl, has swept the nation and caused a genuine crisis.

With two million Americans addicted to pain relievers and another 591,000 struggling with heroin addiction in 2015, this epidemic has affected people across the country of all walks of life. There’s no single type of person who becomes an addict.

Why Put This Medicine in Emergency Kits?

HealthFirst has seen evidence of opioid overdoses in the dental office. Despite your best efforts to keep patients safe, you can’t control the behavior of patients or their families. As this crisis continues, dental professionals should be prepared to address overdoses with a form of naloxone, such as NARCAN.

What is NARCAN?

NARCAN Nasal Spray contains naloxone, which reverses and stops the effects of opioids. When a patient overdoses on opioids, you can quickly administer this drug to restore breathing and stop the overdosing process. In some cases, you may need to deliver subsequent doses.

While patients may experience uncomfortable withdrawal symptoms after receiving naloxone, there are no known life-threatening side effects of this drug. When weighed against the potentially fatal effects of an opioid overdose, it’s clear that naloxone is a smart option. NARCAN Nasal Spray provides an easy way to administer this life-saving medication.

HealthFirst is proud to offer dentists the basic SM Series emergency medical kit with the life-saving drug, NARCAN. Learn more about HealthFirst’s emergency kits.

Read more at healthfirst.com

HealthFirst

Part of this channel

HealthFirst

Practice-ready solutions for dental and medical offices nationwide.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512